Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.
Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle
Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers
In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.
Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium |
9-46027 |
CHI Scientific |
5 x 100 ml |
Ask for price |
Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody |
20-abx148333 |
Abbexa |
|
|
|
Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells |
9-80027 |
CHI Scientific |
1 x 100 ml |
Ask for price |
Breast cancer and normal tissue array with stage and grade info |
BR8012 |
TissueArray |
each |
EUR 306 |
Description: Breast cancer and normal tissue array with stage and grade info, 40 cases/80 cores, replaced by BR8014 |
Human tumor marker CA549 for breast cancer ELISA Kit |
SL3271Hu |
Sunlong |
96 Tests |
EUR 468 |
|
BSA (Standard Grade) |
30-AB70 |
Fitzgerald |
1 kg |
EUR 1078.8 |
Description: Standard Grade Bovine Serum Albumin (99% pure) |
Gastrointestinal Cancer Antigen (CA 19-9), antigen grade |
CA1991-N-10 |
Alpha Diagnostics |
10 KU |
EUR 634.8 |
Breast Cancer and 8 types of tumor (middle advanced stage)tissue array |
BR20838a |
TissueArray |
each |
EUR 474 |
Description: Breast Cancer and 8 types of tumor (middle advanced stage)tissue array, including pathology grade, TNM/stage with IHC Her-2 results, 118 cases/208 cores (core size 1.5mm), replacing BR20838 |
Breast cancer |
BR1008b |
TissueArray |
each |
EUR 306 |
Description: Breast cancer, lymph node metastatic carcinoma and adjacent normal tissue array, including pathology grade, TNM, clinical stage, and ER/PR/Her2 result, 100 cases/100 cores, replacing BR1008a |
Breast cancer |
BR724 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer, adjacent and adjacent normal tissue array, 66 cases/72 cores |
Breast cancer |
BR725 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer, adjacent and adjacent normal tissue array, 68 cases/72 cores |
Breast cancer with cancer adjacent breast tissue array |
BC081116e |
TissueArray |
each |
EUR 306 |
Description: Breast cancer with cancer adjacent breast tissue array, including invasive carcinoma of no special type, breast carcinoma with apocrine differentiation and AT tissue,pat hology grade, IHC (ER/PR/Her-2/Ki67) info, TNM/Stage (AJCC 7th edition), 107 cases/110 cores (core size 1.5mm), replacing BC081116d |
Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues |
Z7020007 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Circulating tumor cell breast cancer detection kit
(anti-HER-2 Ab Magbeads) |
E601CM003 |
EnoGene |
20 tests |
EUR 2500 |
CancerSeq™ Paraffin Tissue Tumor Block: Breast |
T2235086-SB |
Biochain |
1 Block |
EUR 4014 |
Breast cancer TMA |
BR602 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer TMA, 3 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 57 cases/60 cores (Core Size 1.5mm), recent tear collections |
CancerSeq™ Paraffin Tissue Tumor Slides: Breast |
T2235086-ST |
Biochain |
5 Slides |
EUR 572 |
Breast cancer with matched cancer adjacent breast tissue array |
BR804b |
TissueArray |
each |
EUR 306 |
Description: Breast cancer with matched cancer adjacent breast tissue array, including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2 and Ki67), 40 cases/80 cores, replacing BR804a |
Breast cancer with breast tissue array |
BC08118a |
TissueArray |
each |
EUR 258 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores (core size 1.0mm), replacing BC08118 |
Breast cancer with breast tissue array |
BR2085d |
TissueArray |
each |
EUR 546 |
Description: Breast cancer with breast tissue array, including pathology grad, TNM and clinical stage, 188 cases/208 cores, replacing BR2085c |
Breast cancer with breast tissue array |
BR246d |
TissueArray |
each |
EUR 66 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage (reference AJCC 7th version), 12 cases/24 cores, replacing BR246c |
Breast cancer with breast tissue array |
BR482 |
TissueArray |
each |
EUR 198 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 24 cases/48 cores |
Breast cancer with breast tissue array |
BR720 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge (reference AJCC 7th version), 72 cases/72 cores |
Breast cancer with breast tissue array |
T087d |
TissueArray |
each |
EUR 66 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c |
Breast cancer with breast tissue array |
T088d |
TissueArray |
each |
EUR 66 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T088c |
Breast Cancer Exosome |
P141-BR |
101Bio |
- |
Ask for price |
Breast Tumor Tissue Array - duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and |
Z7020004 |
Biochain |
5 slides |
EUR 1293 |
Breast Tumor Tissue Array - Duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and |
Z7020005 |
Biochain |
5 slides |
EUR 1293 |
Breast Tumor Tissue Array - Duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal an |
Z7020008 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Breast Tumor Tissue Array - Duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal an |
Z7020009 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Human Cancer PrimaCell4: Breast Tumor Cells Growth Supplements with Serum (for 500 ml medium) |
9-47027 |
CHI Scientific |
1 Set |
Ask for price |
CancerSeq™ Plus Paraffin Tissue Tumor Sections: Breast |
T2235086-SC |
Biochain |
5 curls |
EUR 779 |
Breast cancer tissue array with cancer adjacent breast tissue as control |
BR208a |
TissueArray |
each |
EUR 474 |
Description: Breast cancer tissue array with cancer adjacent breast tissue as control, including TNM, clinical stage and pathology grade, 69 cases/ 207 cores. |
Breast cancer (including one case of male breast cancer) with adjacent normal breast tissue array |
BC081120g |
TissueArray |
each |
EUR 306 |
Description: Breast cancer (including one case of male breast cancer) with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage (AJCC 7th edition) with IHC results ER/PR/Her2/Ki67,110 cases/110 cores (core size 1.0 mm), replacing BC081120f |
Proteinase K, Recombinant, Standard Grade |
9250-100 |
Biovision |
each |
EUR 124.8 |
Proteinase K, Recombinant, Standard Grade |
9250-10G |
Biovision |
each |
EUR 4627.2 |
Proteinase K, Recombinant, Standard Grade |
9250-1G |
Biovision |
each |
EUR 548.4 |
Proteinase K, Recombinant, Standard Grade |
9250-500 |
Biovision |
each |
EUR 314.4 |
Proteinase K, Recombinant, Standard Grade |
9251-100 |
Biovision |
each |
EUR 1266 |
Proteinase K, Recombinant, Standard Grade |
9251-25 |
Biovision |
each |
EUR 352.8 |
Proteinase K, Recombinant, Standard Grade |
9251-5 |
Biovision |
each |
EUR 144 |
Breast cancer with matched breast tissue array |
BR251e |
TissueArray |
each |
EUR 60 |
Description: Breast cancer with matched breast tissue array, including pathology grade, IHC info (ER,PR,Her-2,Ki67),TNM\Stage, 6 cases/24 cores (core size 1.5mm), replacing BR251d |
Breast Cancer Exosome RNA |
P241-BR |
101Bio |
- |
Ask for price |
Multiple breast cancer with breast tissue array |
BR087e |
TissueArray |
each |
EUR 48 |
Description: Multiple breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing BR087d |
Breast cancer tissue array |
BR042b |
TissueArray |
each |
EUR 78 |
Description: Breast cancer tissue array, including TNM and pathology grade, 4 cases/4 cores, replacing BR042a |
Breast cancer tissue array |
BR1006a |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores (core size 1.0mm), replacing BR1006 |
Breast cancer tissue array |
BR1141a |
TissueArray |
each |
EUR 354 |
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, IHC marker (ER, PR, HER2 and Ki-67), 114 cases/114 cores, replacing BR1141 |
Breast cancer tissue array |
BR1401 |
TissueArray |
each |
EUR 414 |
Description: Breast cancer tissue array, including TNM and pathology grade, IHC markers ER/PR/Her-2 results, 140 cases/140 cores (core size 1.0mm) |
Breast cancer tissue array |
BR1503f |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, including TNM and pathology grade, with IHC results of Her-2\ER\PR\Ki67, 75 cases/ 150 cores, replacing BR1503e |
Breast cancer tissue array |
BR1505e |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, including pathology grade, TNM, clinical stage, and IHC(HER2/ER/PR/Ki67), 75 cases/150 cores, replacing BR1505d |
Breast cancer tissue array |
BR2161 |
TissueArray |
each |
EUR 546 |
Description: Breast cancer tissue array, including TNM and pathology grade, 216 cases/216 cores |
Breast cancer tissue array |
BR247a |
TissueArray |
each |
EUR 234 |
Description: Breast cancer tissue array, with normal tissue, including TNM and pathology grade, IHC marker (HER2), 24 cases/48 cores replacing BR247 |
Breast cancer tissue array |
BR488 |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, including pathology grade, TNM, clinical stage (AJCC 7th edition), and IHC marker(ER,PR,Her-2), 48 cases/48 cores |
Breast cancer tissue array |
BR501 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer tissue array, including TNM and pathology grade, 50 cases/ 50 cores (core size 1.5mm) |
Breast cancer tissue array |
BR8015a |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases/80 cores, replacing BC08014 |
Breast cancer tissue array |
BR964 |
TissueArray |
each |
EUR 222 |
Description: Breast cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/96 cores |
Breast cancer tissue array |
T089c |
TissueArray |
each |
EUR 48 |
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores(1.5mm), replacing T089b |
Advanced stage breast cancer and normal breast tissue array |
BR1191 |
TissueArray |
each |
EUR 306 |
Description: Advanced stage breast cancer and normal breast tissue array, including pathology grade, TNM and clinical stage (AJCC 8.0), ER\PR\HER-2\Ki-67 marker, 119 cases/119 cores, (1.5mm) |
Breast normal tissue with breast cancer tissue array |
BRN801c |
TissueArray |
each |
EUR 270 |
Description: Breast normal tissue with breast cancer tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BRN801b |
Standard grade heat shock BSA powder, pH 7 |
BAH62-0050 |
Equitech |
50gm |
EUR 308.88 |
|
Standard grade heat shock BSA powder, pH 7 |
BAH62-0100 |
Equitech |
100gm |
EUR 388.44 |
|
Standard grade heat shock BSA powder, pH 7 |
BAH62-0500 |
Equitech |
500gm |
EUR 511.68 |
|
Standard grade heat shock BSA powder, pH 7 |
BAH62-1000 |
Equitech |
1KG |
Ask for price |
|
Standard grade heat shock BSA powder, pH 7 |
BAH62-10000 |
Equitech |
10KG |
Ask for price |
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-0050 |
Equitech |
50gm |
EUR 308.88 |
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-0100 |
Equitech |
100gm |
EUR 388.44 |
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-0500 |
Equitech |
500gm |
EUR 511.68 |
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-1000 |
Equitech |
1KG |
Ask for price |
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-10000 |
Equitech |
10KG |
Ask for price |
|
Breast cancer with adjacent normal breast tissue array |
BR1921c |
TissueArray |
each |
EUR 546 |
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR and Her-2), 189 cases/192 cores, replacing BR1921b |
Breast cancer with adjacent normal breast tissue array |
BR803c |
TissueArray |
each |
EUR 258 |
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BR803b |
Breast cancer with adjacent normal breast tissue array |
BR901a |
TissueArray |
each |
EUR 270 |
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 45 cases/90 cores, replacing BR901 |
Breast Cancer Anti-Estrogen Resistance 1 |
PR27245 |
Neuromics |
2 ug |
EUR 229.2 |
Breast cancer test tissue array |
T086e |
TissueArray |
each |
EUR 66 |
Description: Breast cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replacing T086d |
Bovine Serum Albumin, Fraction V - Standard Grade |
22070008-1 |
Bio-WORLD |
25 g |
EUR 44.19 |
Description: BSA |
Bovine Serum Albumin, Fraction V - Standard Grade |
22070008-2 |
Bio-WORLD |
50 g |
EUR 68.62 |
Description: BSA |
Bovine Serum Albumin, Fraction V - Standard Grade |
22070008-3 |
Bio-WORLD |
100 g |
EUR 127.13 |
Description: BSA |
Bovine Serum Albumin, Fraction V - Standard Grade |
22070008-4 |
Bio-WORLD |
250 g |
EUR 248.48 |
Description: BSA |
Bovine Serum Albumin, Fraction V - Standard Grade |
22070008-5 |
Bio-WORLD |
500 g |
EUR 447.06 |
Description: BSA |
Bovine Serum Albumin, Fraction V - Standard Grade |
22070008-6 |
Bio-WORLD |
1 kg |
EUR 774.79 |
Description: BSA |
Late stage breast cancer tissue array |
BR1922 |
TissueArray |
each |
EUR 546 |
Description: Late stage breast cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases/192 cores |
Cancer of the breast, 102 cases (1.5mm) |
BRC1021 |
Pantomics |
1 |
EUR 300 |
Description: Breast cancer tissue array, 102 cases of normal/benign (5 cases) and cancer (97 cases) tissues, with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Cancer of the breast, 228 cases (1.1mm) |
BRC2281 |
Pantomics |
1 |
EUR 552 |
Description: Breast cancer tissue array containing 8 cases of normal/benign conditions and 220 cases of cancers with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx171475 |
Abbexa |
|
|
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx324781 |
Abbexa |
|
|
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx129227 |
Abbexa |
-
EUR 510.00
-
EUR 159.60
-
EUR 1446.00
-
EUR 693.60
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
PRB-5069 |
Cell Biolabs |
96 assays |
EUR 686.4 |
Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
PRB-5069-5 |
Cell Biolabs |
5 x 96 assays |
EUR 2739.6 |
Cancer Antigen 15-3 MUC 1 Antigen (Human Milk) |
VAng-Cr3871-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
Breast disease spectrum (breast cancer progression) tissue array |
BR2082c |
TissueArray |
each |
EUR 546 |
Description: Breast disease spectrum (breast cancer progression) tissue array, including pathology grade, TNM and clinical stage, IHC marker (ER, PR, HER2 and Ki-67), 186 cases/192 cores, replacing BR2082b |
Breast cancer with matched or unmatched breast tissue array |
BR802c |
TissueArray |
each |
EUR 270 |
Description: Breast cancer with matched or unmatched breast tissue array, including pathology grade, TNM and clinical stage, 53 cases/80 cores, replacing BR802b |
Breast tumor tissue array (15 of 25) |
BR20821 |
TissueArray |
each |
EUR 474 |
Description: Breast tumor tissue array (15 of 25), including TNM, clinical stage, pathology grade and IHC markers (ER, PR, Her-2) results,104 cases/208 cores |
Breast cancer Exosome Isolation Kit |
E601E002 |
EnoGene |
20 tests |
EUR 2500 |
Breast cancer tissue array with adjacent normal breast tissue |
BR8011a |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array with adjacent normal breast tissue, including TNM, clinical stage, pathology grade and DCIS, 80 cases/80 cores, replacing BR8011 |
Cancer of the breast, 75 cases (1.1mm), set 3 |
BRC1503 |
Pantomics |
1 |
EUR 300 |
Description: Breast cancer tissue array, set 3, non-overlapping with BRC1501, BRC1502, BRC1504 to BRC15011,150 cores from normal/benign (5 cases) and cancer (70 cases) tissues in duplicates with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) |
4-RPG768Hu01 |
Cloud-Clone |
-
EUR 601.69
-
EUR 284.40
-
EUR 1926.34
-
EUR 722.11
-
EUR 1324.22
-
EUR 477.60
-
EUR 4635.84
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Breast Cancer Anti-Estrogen Resistance 3 expressed in: E.coli |
Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) |
RPU53453-100ug |
Biomatik Corporation |
100ug |
EUR 552.2 |
Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) |
RPU53453-1mg |
Biomatik Corporation |
1mg |
EUR 2446.6 |
Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) |
RPU53453-50ug |
Biomatik Corporation |
50ug |
EUR 443.3 |
Breast Cancer Metastasis Suppressor 1 |
PR27265 |
Neuromics |
2 ug |
EUR 229.2 |
Cancer of the breast, 49 cases (2mm) |
BRC491 |
Pantomics |
1 |
EUR 228 |
Description: Breast cancer tissue array, non-overlapping with BRC711, 49 cases of normal/benign and cancer tissues with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Cancer of the breast, 71 cases (1.1mm) |
BRC711 |
Pantomics |
1 |
EUR 228 |
Description: Breast cancer tissue array, non-overlapping with BRC491, 71 cases of normal/benign and cancer tissues with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 7.0 |
7915-100 |
Biovision |
each |
EUR 705.6 |
Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 7.0 |
7915-25 |
Biovision |
each |
EUR 274.8 |
Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 7.0 |
7915-5 |
Biovision |
each |
EUR 144 |
Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 5.2 |
7916-100 |
Biovision |
each |
EUR 705.6 |
Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 5.2 |
7916-25 |
Biovision |
each |
EUR 274.8 |
Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 5.2 |
7916-5 |
Biovision |
each |
EUR 144 |
Breast Cancer Anti-Estrogen Resistance 1 Protein |
20-abx262743 |
Abbexa |
-
EUR 393.60
-
EUR 7676.40
-
EUR 276.00
|
|
|
Vitamin A Reference Standard (USP grade powder) |
51R-U716002 |
Fitzgerald |
10 pack |
EUR 619.2 |
Description: Vitamin A Reference Standard (USP grade powder) chemical reference substance |
Breast cancer and normal tissue array |
BR485 |
TissueArray |
each |
EUR 414 |
Description: Breast cancer and normal tissue array, including TNM and pathology grade, 2 serial sections, 48 cases/96 cores |
Breast cancer and normal tissue array |
BR8014 |
TissueArray |
each |
EUR 306 |
Description: Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 40 cases/80 cores, replaced by BR8015 |
Single Donor Human Breast Cancer Serum |
ISERSBSC |
Innovative research |
each |
EUR 209 |
|
Description: Single Donor Human Breast Cancer Serum |
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Protein |
20-abx168253 |
Abbexa |
-
EUR 844.80
-
EUR 343.20
-
EUR 2598.00
-
EUR 994.80
-
EUR 594.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer Cell Protein 2 (BRCC2) Antibody |
20-abx141388 |
Abbexa |
-
EUR 444.00
-
EUR 727.20
-
EUR 360.00
|
|
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
20-abx133658 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
abx025588-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
abx025588-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
20-abx013807 |
Abbexa |
-
EUR 376.80
-
EUR 117.60
-
EUR 477.60
-
EUR 594.00
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
20-abx134976 |
Abbexa |
-
EUR 427.20
-
EUR 644.40
-
EUR 260.40
|
|
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
abx218562-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
abx432398-200ul |
Abbexa |
200 ul |
EUR 460.8 |
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
abx010337-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
Single Donor Human Breast Cancer Plasma |
IPLASBSC |
Innovative research |
each |
EUR 209 |
|
Description: Single Donor Human Breast Cancer Plasma |
Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid) |
VAng-Cr3872-10kU |
Creative Biolabs |
10 kU |
EUR 1363.2 |
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid. |
Breast cancer with matched metastatic carcinoma or breast tissue array |
BRM961a |
TissueArray |
each |
EUR 384 |
Description: Breast cancer with matched metastatic carcinoma or breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR and Her-2), 49 cases/96 cores |
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Polyclonal Antibody |
CAU22164-100ul |
Biomatik Corporation |
100ul |
EUR 235.2 |
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Polyclonal Antibody |
CAU22164-200ul |
Biomatik Corporation |
200ul |
EUR 294 |
Breast cancer tissue array (Her-2: 3+/2+/1+/0) |
BR082e |
TissueArray |
each |
EUR 78 |
Description: Breast cancer tissue array (Her-2: 3+/2+/1+/0), including pathology grade, TNM, clinical stage and IHC marker (ER, PR, Her-2 and Ki67), 4 cases/8 cores, replaced by BR082f |
Multiple types breast cancer tissue array |
BR1003a |
TissueArray |
each |
EUR 306 |
Description: Multiple types breast cancer tissue array, including pathology grade, TNM and clinical stage, 47 cases/101 cores, replacing BR1003 |
High-density breast cancer tissue array |
BR6161 |
TissueArray |
each |
EUR 954 |
Description: High-density breast cancer tissue array, with stage, grade and normal breast tissue, 322 cases/616 cores |
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) CLIA Kit |
20-abx495288 |
Abbexa |
-
EUR 9567.60
-
EUR 5095.20
-
EUR 1177.20
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Cancer Antigen CA 15-3 Protein (Human Milk) |
VAng-Wyb8631-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: CA 15-3 (Breast Cancer Antigen), Antigen Grade, Cancer antigen from Human Milk, 33.0 kIU/mL. |
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit |
20-abx150793 |
Abbexa |
-
EUR 8853.60
-
EUR 4719.60
-
EUR 1093.20
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit |
SEG768Hu-10x96wellstestplate |
Cloud-Clone |
10x96-wells test plate |
EUR 5677.8 |
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in serum, plasma, tissue homogenates and other biological fluids. |
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit |
SEG768Hu-1x48wellstestplate |
Cloud-Clone |
1x48-wells test plate |
EUR 572.76 |
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in serum, plasma, tissue homogenates and other biological fluids. |
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit |
SEG768Hu-1x96wellstestplate |
Cloud-Clone |
1x96-wells test plate |
EUR 766.8 |
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in serum, plasma, tissue homogenates and other biological fluids. |
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit |
SEG768Hu-5x96wellstestplate |
Cloud-Clone |
5x96-wells test plate |
EUR 3090.6 |
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in serum, plasma, tissue homogenates and other biological fluids. |
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit |
4-SEG768Hu |
Cloud-Clone |
-
EUR 5738.40
-
EUR 3031.20
-
EUR 768.00
|
- 10 plates of 96 wells
- 5 plates of 96 wells
- 1 plate of 96 wells
|
|
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in samples from Serum, plasma, tissue homogenates and other biological fluids. with no significant corss-reactivity with analogues from other species. |
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit |
EKN43917-48T |
Biomatik Corporation |
48T |
EUR 378.7 |
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.